CN102138953B - Application of chorispora bungeana or extract thereof in preparation of medicaments for preventing and treating cardiovascular and cerebrovascular diseases - Google Patents
Application of chorispora bungeana or extract thereof in preparation of medicaments for preventing and treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN102138953B CN102138953B CN 201010117378 CN201010117378A CN102138953B CN 102138953 B CN102138953 B CN 102138953B CN 201010117378 CN201010117378 CN 201010117378 CN 201010117378 A CN201010117378 A CN 201010117378A CN 102138953 B CN102138953 B CN 102138953B
- Authority
- CN
- China
- Prior art keywords
- extract
- chorispora bungeana
- chorispora
- bungeana
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and provides application of chorispora bungeana or an extract thereof in the preparation of medicaments for preventing and treating cardiovascular and cerebrovascular diseases. The extract of the chorispora bungeana comprises a water extract and an alcohol extract of the chorispora bungean. Studies indicate that the chorispora bungeana or the extract thereof has the obvious effects of resisting cerebral ischemia, cerebral anoxia, cerebral thrombosis and vascular dementia in human bodies, has small side effect and can be taken for a long term.
Description
Technical field
The invention belongs to medical technical field, be specifically related to the preparation of Chorispora bungeana extract, the application in preparation control cardiovascular and cerebrovascular diseases medicament of Chorispora bungeana or its extract.
Background technology
Cardiovascular and cerebrovascular disease is in the world today mankind to be threatened one of maximum disease, and its M ﹠ M surpasses cancer and leaps to the first in the world.The data demonstration of ministry of Health of China announcement in 2008, mortality of cardio and cerebral vascular disease is high in the general mortality rate of Chinese population ranks first, and urbanite's deaths from heart disease rate is 19.65%, and the cerebrovascular disease mortality rate is 19.62%.Wherein, have the cerebrovascular disease of " sickness rate is high, disability rate is high, mortality rate is high, relapse rate is high; complication is many " characteristics, even adopt most advanced, the most perfect treatment means, still can have cerebrovascular disease survivor life more than half not take care of oneself fully.At present, the cerebrovascular disease medicament treatment comprises antioxidation, antiinflammatory, anticoagulation, antiplatelet aggregation and thromboembolism treatment etc.But the most of pathways of drug action that has gone on the market is single, and therefore unsatisfactory curative effect, even cause the aggravation of the state of an illness seeks the direction that can useful effect becomes Developing in the medicine of a plurality of Pathophysiology links.
Chorispora bungeana (Chorispora bungeana Fisch.et Mey.) is the perennial alpine periglacial plant of Cruciferae, mainly is distributed on the subalpine meadow, grassland, gravel matter hillside at height above sea level 2600～4000m place, Xinjiang.Abominable living environment has brought up the effect of Chorispora bungeana uniqueness, (Ah Yi tells that antiperspirant but the preparation method and the treating cerebral ischemia that have no its extract of bibliographical information are studied, Tan Dunyan, Li Zhijun, Deng. the relation research [J] of the structure of Chorispora bungeana nutrition organs and environment. Xinjiang Agricultural Univ's journal, 1998,21 (4): 273-277; Han Yan, Li Zhengyan, Yue Xiule, etc. the real-time quantitative analysis [J] that the clone of Chorispora bungeana iron transporter gene coded sequence and resistance thereof are expressed. Chinese biological chemistry and molecular biosciences journal, 2008,24 (6): 549-555; Zhang Lijing. the clone of Chorispora bungeana ferritin gene CbFer, expression and anti-oxidation function analysis [D] thereof. Lanzhou: Lanzhou University, 2006).
Summary of the invention
The invention provides the new purposes of Chorispora bungeana or its extract, be that Chorispora bungeana or its extract are for the preparation of the application of control cardiovascular and cerebrovascular diseases medicament, application especially for preparation control cerebrovascular disease medicament can be used for prevention and the treatment of cerebral thrombosis, cerebral ischemia, cerebral embolism, the multiple cerebrovascular disease of vascular dementia.The invention provides a kind of pharmaceutical composition that comprises Chorispora bungeana or its extract and conventional pharmaceutical carrier, it is characterized in that described pharmaceutical composition is the preparation that adopts the oral or non-oral route mode administration that conventional formulation technique is prepared from.
The invention provides the method for prevention or treatment cardiovascular and cerebrovascular disease, comprise to Patients with Cardiovascular/Cerebrovascular Diseases giving Chorispora bungeana or its extract or pharmaceutical composition noted earlier.
Chorispora bungeana provided by the invention or its extract can prolonged application, and have obvious prevention or improve the effect of heart and brain damage, non-evident effect, cheap.
Adopt the Chorispora bungeana extract of various distinct methods preparations on not impact of purposes of the present invention.
The specific embodiment
Cardiovascular and cerebrovascular disease is the general designation of cardiovascular diseases and cerebrovascular, ischemic or hemorrhage occur by the heart due to hyperlipemia, hyperlipidemia, atherosclerosis, thrombosis, the hypertension etc., brain and body tissue in general reference, comprise coronary heart diseases and angina pectoris, myocardial ischemia, cerebral ischemia, cerebral hemorrhage, cerebral anoxia, cerebral embolism, brain dementia etc.
The invention provides the application in the medicine of preparation control cardiovascular and cerebrovascular disease of Chorispora bungeana or its extract, particularly Chorispora bungeana or its extract application in preparation control cerebrovascular disease medicament is including, but not limited to cerebrovascular disease such as cerebral ischemia, cerebral anoxia, cerebral thrombosis, vascular dementia.
After the gravel hillside gathered near the Chorispora bungeana plant can from height above sea level be the Tianshan Mountains of 3700～4000m 7～August of every year, transport laboratory back together with earth in carton on the sunny side, the water spray maintenance is moistening in the way.The high approximately 3～10cm of plant, by white pubescence, underground have a thick fleshy tap root, butt has upright root stock, and leaf is most, and base is given birth to, drastic crack is to totally cleaving, blade is oval, and (Ah Yi tells your antiperspirant, Tan Dunyan to pinniform, Li Zhijun, Deng. the relation research [J] of the structure of Chorispora bungeana nutrition organs and environment. Xinjiang Agricultural Univ's journal, 1998,21 (4): 273-277).
The Chorispora bungeana extract can prepare in the following manner:
(1) gets fresh Chorispora bungeana Herb, clean the removal of impurity, use pulverizer to pulverize, put in the 1000ml round-bottomed flask, 4 times of water soakings that add medical material weight are 1h approximately, and heat decocts, and extracts three times, each 1.5h, filter (with 80 order nylon cloth) merging filtrate, the centrifugal 10min of 3000rpm, get supernatant concentration, lyophilization becomes dry extract namely to get the Chorispora bungeana water extract.
(2) get fresh Chorispora bungeana Herb, clean the removal of impurity, oven dry, the use pulverizer is pulverized, and puts in the 1000ml round-bottomed flask, and 4 times of water soakings that add medical material weight are 1h approximately, heat decocts, extract three times, each 1.5h filters (with 80 order nylon cloth), merging filtrate, the centrifugal 10min of 3000rpm gets supernatant concentration, and lyophilization becomes dry extract namely to get the Chorispora bungeana water extract.
(3) get fresh Chorispora bungeana Herb, clean the removal of impurity, use pulverizer to pulverize, put in the 1000ml round-bottomed flask, 60%～80% (v/v) soak with ethanol that adds 4 times of weight of medical material is 1h approximately, reflux, extract, 3 times, each 1h filters (with 80 order nylon cloth), merging filtrate, the centrifugal 10min of 3000rpm gets supernatant concentration, and lyophilization becomes dry extract namely to get the Chorispora bungeana ethanol extract.
(4) get fresh Chorispora bungeana Herb, clean the removal of impurity, oven dry, the use pulverizer is pulverized, put in the 1000ml round-bottomed flask, 60%～80% (v/v) soak with ethanol that adds 4 times of weight of medical material is 1h approximately, reflux, extract, 3 times, each 1h, filter (with 80 order nylon cloth) merging filtrate, the centrifugal 10min of 3000rpm, get supernatant concentration, lyophilization becomes dry extract namely to get the Chorispora bungeana ethanol extract.
Chorispora bungeana of the present invention or its extract can be according to clinical needs, add corresponding pharmaceutical carrier, exist with dosage forms such as tablet, pill, granule, capsule, suspension, solution, syrup, injection, cream, ointment, gel, spray, chewing agent or patches.
Chorispora bungeana of the present invention or its extract can according to clinical needs, adopt oral or non-oral way medication, the preferred oral administering mode.
When Chorispora bungeana of the present invention or its extract formulation adopt the oral way medication, the preferred 0.05-50g/ people of human dosage/day (being equivalent to the crude drug amount), wherein 0.5-25g/ people/day (being equivalent to the crude drug amount) more preferably, most preferably be 2.5-5g/ people/day (being equivalent to the crude drug amount).
The present invention will be described below in conjunction with experimental example, but the present invention is not limited to this embodiment.
The preparation of embodiment 1 Chorispora bungeana extract
Annual 7～August from height above sea level be near Tianshan Mountains of 3700～4000m on the sunny side the gravel hillside gather the Chorispora bungeana plant, in carton, transport laboratory back together with earth, water spray keeps moistening in the way.Get the fresh Chorispora bungeana Herb of 80g, clean the removal of impurity, use pulverizer to pulverize, put in the 1000ml round-bottomed flask, 4 times of water soakings that add medical material weight are 1h approximately, and heat decocts, and extracts three times, each 1.5h, filter (with 80 order nylon cloth) merging filtrate, the centrifugal 10min of 3000rpm, get supernatant concentration, lyophilization becomes dry extract namely to get 1.7g Chorispora bungeana water extract.
The preparation of embodiment 2 Chorispora bungeana extracts
Annual 7～August from height above sea level be near Tianshan Mountains of 3700～4000m on the sunny side the gravel hillside gather the Chorispora bungeana plant, in carton, transport laboratory back together with earth, water spray keeps moistening in the way.Get the fresh Chorispora bungeana Herb of 80g, clean the removal of impurity, oven dry, the use pulverizer is pulverized, and puts in the 1000ml round-bottomed flask, and 4 times of water soakings that add medical material weight are 1h approximately, heat decocts, extract three times, each 1.5h filters (with 80 order nylon cloth), merging filtrate, the centrifugal 10min of 3000rpm gets supernatant concentration, and lyophilization becomes dry extract namely to get 6.9g Chorispora bungeana water extract.
The preparation of embodiment 3 Chorispora bungeana extracts
Annual 7～August from height above sea level be near Tianshan Mountains of 3700～4000m on the sunny side the gravel hillside gather the Chorispora bungeana plant, in carton, transport laboratory back together with earth, water spray keeps moistening in the way.Get the fresh Chorispora bungeana Herb of 80g, clean the removal of impurity, use pulverizer to pulverize, put in the 1000ml round-bottomed flask, 60%～80% (v/v) soak with ethanol that adds 4 times of weight of medical material is 1h approximately, reflux, extract, 3 times, each 1h filters (with 80 order nylon cloth), merging filtrate, the centrifugal 10min of 3000rpm gets supernatant concentration, and lyophilization becomes dry extract namely to get 1.9g Chorispora bungeana ethanol extract.
The preparation of embodiment 4 Chorispora bungeana extracts
Annual 7～August from height above sea level be near Tianshan Mountains of 3700～4000m on the sunny side the gravel hillside gather the Chorispora bungeana plant, in carton, transport laboratory back together with earth, water spray keeps moistening in the way.Get the fresh Chorispora bungeana Herb of 80g, clean the removal of impurity, oven dry, the use pulverizer is pulverized, put in the 1000ml round-bottomed flask, 60%～80% (v/v) soak with ethanol that adds 4 times of weight of medical material is 1h approximately, reflux, extract, 3 times, each 1h, filter (with 80 order nylon cloth) merging filtrate, the centrifugal 10min of 3000rpm, get supernatant concentration, lyophilization becomes dry extract namely to get 7.3g Chorispora bungeana ethanol extract.
The anti-cerebral thrombosis research of embodiment 5 Chorispora bungeana extracts
1. materials and methods
1.1 laboratory animal: the healthy adult male Wistar rat, the SPF/VAF level, body weight 250～300g is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering: SCXK (capital) 2007-0001.Using the unity and coherence in writing function of health food SPF of inspection center level experimental animal room in the Beijing Union University before the experiment conforms a week.
1.2 reagent: Chorispora bungeana extract: in above-mentioned Preparation Example, prepare; NAOXINTONG JIAONANG: Xianyang Buchang Pharmaceutical Co., Ltd.
1.3 instrument: AR-2140 type ten thousand/electronic balance: prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit Instr Ltd..
1.4 laboratory animal grouping and administration
Extracting male Wistar rat is divided into 5 groups at random: model group, Chorispora bungeana (being equivalent to crude drug amount 5,2.5,1.25g/kg) group, NAOXINTONG JIAONANG (0.324g/kg) group, 24 every group, gastric infusion 14d before the art, every day 1 time.The model group gavage gives the solvent distilled water in contrast.
1.5 thrombosis experiment
With 10% chloral hydrate (350mg/kg, ip) anesthetized rat.Animal heat is maintained 37 ℃.Allow animal lie on the back fixing, cut skin and subcutaneous tissue along cervical midline.Separate right carotid and left side external jugular vein under the operating microscope.Intubate is carried out at two ends, behind the formation rat neck artery-vein bypass 15min, takes out No. 4 silk thread, weighs after filter paper is removed floating blood, namely obtains wet weight of thrombus.The rear thrombosis of will weighing places drying baker, at 60 ℃, takes out behind the dry 4h and weighs, and is the thrombosis dry weight.
1.6 statistical procedures
Experimental result all represents with x ± s, adopts one factor analysis of variance to organize a significance relatively, relatively adopts the t check between sample average.
*Expression P＜0.05 shows that administration group and model group relatively have significant difference;
*Expression P＜0.01 shows that administration group and model group relatively have utmost point significant difference.
2. result
2.1 the Chorispora bungeana extract is on the impact of rat neck arteriovenous thrombus weight
Table 1 Chorispora bungeana extract is on the impact (x ± s, n=8) of rat neck arteriovenous thrombus weight
The thrombus weight of Chorispora bungeana extract group is starkly lower than model group, shows that the Chorispora bungeana extract has anti-cerebral thrombosis effect.
Annotate: compare with model group,
*Expression P＜0.05
*Expression P＜0.01
The research of embodiment 6 Chorispora bungeana extract anti-cerebral ischemias
1. materials and methods
1.1 laboratory animal: the healthy adult male Wistar rat, the SPF/VAF level, body weight 200～250g is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering: SCXK (capital) 2007-0001.Using the unity and coherence in writing function of health food SPF of inspection center level experimental animal room in the Beijing Union University before the experiment conforms a week.
1.2 reagent: Chorispora bungeana: in above-mentioned Preparation Example, prepare; NAOXINTONG JIAONANG: Xianyang Buchang Pharmaceutical Co., Ltd; APC (Aspirin Phenacetin and Caffeine): Hubei Pharmaceutical Co., Ltd.; Chloral hydrate: Tianjin recovery fine chemistry industry institute; Red tetrazolium (2,3,5-triphenyltetrazolium, TTC): Sigma company; MDA, MPO, SOD, Coomassie brilliant blue test kit: bio-engineering research institute is built up in Nanjing; TT, FB test kit: U.S. Pacific Ocean company.
1.3 instrument: AR-2140 type ten thousand/electronic balance: prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit Instr Ltd.; Electric-heated thermostatic water bath: mayor of Beijing bearing instruments and meters company; TGL 16M centrifuge: the triumphant scientific instrument company limited that reaches in Hunan; MH-2 micro oscillator: its woods Bel instrument manufacturing company limited of Haimen, Jiangsu; DY89-II type electric driven glass refiner: NingBo XinZhi Biology Science Co., Ltd; The desk-top drying baker of WG-2003: south, Huiyang electric experimental facilities factory; Microplate reader: U.S. Thermo company; ACL Advance automatic coagulation analyzer: U.S. Beckman Coulter Inc..
1.4 animal grouping and administration
Extracting male Wistar rat is divided into 6 groups at random: sham operated rats, model group, Chorispora bungeana (being equivalent to crude drug amount 5,2.5,1.25g/kg) group, NAOXINTONG JIAONANG (0.324g/kg) group, 24 every group, gastric infusion, every day 1 time.1h after the 5d administration implements operation.
1.5Wistar the making of evaluating focal brain ischemia in rats
Rat is with chloral hydrate 350mg/kg, intraperitoneal injection of anesthesia, lie on the back fixing, the neck median incision, expose successively and separate left carotid (Common carotid artery, CCA), internal carotid artery (Internalcarotid artery, ICA), external carotid artery (External carotid artery, ECA).Close common carotid artery and internal carotid artery with bulldog clamp folder, ligation external carotid artery distal end is opened an osculum at external carotid artery, and the head end circle is blunt and insert internal carotid artery through the fishing line that poly-D-lysine is processed, and intubating length is about 18～20mm in crotch.Ligation internal carotid artery and common carotid artery, fixing fishing line, skin suture (fishing line is reserved a little in external).Behind the ischemia 2h, fixing rat, with fishing line pull out to neck, the external carotid artery crotch, realize again perfusion.Sham operated rats is only separated Where Three Faults Meet, not inaccessible middle cerebral artery.
1.6 function of nervous system's defective scoring
Model group and each medication group rat do function of nervous system's defective scoring, and standards of grading are:
1) carries the rat tail and observe forelimb flexing situation.Stretch to ground such as bilateral forelimb symmetry, count 0 minute; As the offside wrist of performing the operation is bent, counts 1 minute; As the offside elbow flexing of performing the operation, count 2 minutes; As the offside shoulder inward turning of performing the operation, count 3 minutes; As the existing wrist elbow of the offside of performing the operation flexing has again the shoulder inward turning, counts 4 minutes.2) rat is placed on the level ground, push away respectively both shoulders to side shifting, check resistance.Such as bilateral resistance equity and strong, count 0 minute; Resistance slightly descends when promoting rat to the operation offside, counts 1 minute; The resistance moderate descends when promoting animal to the operation offside, counts 2 minutes; Resistance severe descends when promoting rat to the operation offside, counts 3 minutes.3) the two forelimbs of rat are placed on the wire netting, observe the muscular tension of forelimb.Such as bilateral muscle of anterior limb tension force equity and strong, count 0 minute; As slightly descending to operation offside muscle of anterior limb tension force, count 1 minute; As descending to operation offside muscle of anterior limb tension force moderate, count 2 minutes; As descending to operation offside muscle of anterior limb tension force severe, count 3 minutes; 4) rat has and does not stop counting 1 minute to the operation offside person of turn-taking.According to above standard scoring, full marks are 11 minutes, and mark is higher, shows that the rat delayed ischemic neurological deficits is more serious.
1.7 the cerebral infarction scope is measured
Adopt TTC Determination Staining cerebral infarction scope.To take out rapidly complete brain behind the animal broken end, the crown brain sheet that is cut into 2mm is hatched 30min in (with the phosphate buffered saline(PBS) preparation) 37 ℃ of water-baths in 2%TTC solution.Infarction tissue is white in color, and normal surrounding tissue is rose.Then fixing in 10% neutral formalin solution.Every brain sheet tow sides are scanned, obtain infarcted region and non-Infarct area with the image analysis software integration.
1.8 the mensuration of brain water content
After ischemia 2h pours into 22h again, the rapid broken end of mice is got brain, survey brain water content with dried wet method, on ice cube, get rapidly brain, the cerebral tissue that takes out is placed in the culture dish that the moistening qualitative filter paper of normal saline is arranged in, in case the moisture evaporation, the while is removed pia mater encephali and the sludged blood on brain cortex surface fast.Accurately take by weighing brain weight with one thousandth sky chessboard, then place 100 ℃ of baking oven 24h after, again weigh, be relative water content with (1-dry weight/weight in wet base) * 100%.
1.9 coagulation function is measured
After pouring into 22h again, postcava is got blood 3ml, measures thrombin time of blood plasma (TT) and fibrinogen content (FB) with ACL Advance automatic coagulation analyzer.
1.10 cerebral tissue MDA content, MPO and SOD determination of activity
Rat is sacrificed by decapitation after cerebral ischemia 2h pours into 22h again, fast fetching brain on ice pan.Weigh, add ice-cold normal saline by 1: 9 (W/V), make 10% brain tissue homogenate.Homogenate with the centrifugal 10min of 3000r/min, is got supernatant, preserve to be measured at-70 ℃ of ultra cold storage freezers.Press the test kit description and measure MDA content, MPO activity and SOD activity.Protein content determination adopts the Coomassie brilliant blue method.
1.11 statistical procedures
Experimental result all represents with x ± s, adopts one factor analysis of variance to organize a significance relatively, relatively adopts the t check between sample average.
*Expression P＜0.05 shows that administration group and model group relatively have significant difference;
*Expression P＜0.01 shows that administration group and model group relatively have utmost point significant difference.
2 results
2.1 the Chorispora bungeana extract is on the impact of rat function of nervous system defective, cerebral infarction scope, brain water content
The result is as shown in table 2, compare with sham operated rats, the defective scoring of model group function of nervous system, cerebral infarction scope and brain water content obviously increase, the Chorispora bungeana extract is dose dependent ground and reduces function of nervous system's defective scoring, reduce the cerebral infarction scope, alleviate cerebral edema, show that Chorispora bungeana has the anti-cerebral ischemia reperfusion injury and protect.
Table 2 Chorispora bungeana extract is on the impact (x ± s, n=8) of rat function of nervous system defective, cerebral infarction scope, brain water content
Compare with model group,
*Expression P＜0.05
*Expression P＜0.01
2.2 the Chorispora bungeana extract is on the impact of rat coagulation function
Ischemia 2h pours into 22h again can cause that the rat plasma thrombin time shortens significantly, and fibrinogen content raises significantly.Compare with model group, Chorispora bungeana can prolong thrombin time of blood plasma significantly, reduces fibrinogen content, shows that the Chorispora bungeana treating cerebral ischemia is relevant with anticoagulant active.
Table 3 Chorispora bungeana extract is on the impact (x ± s, n=8) of rat coagulation function
Compare with model group,
*Expression P＜0.05
*Expression P＜0.01
2.3 the Chorispora bungeana extract is on the impact of the MPO of rat cerebral tissue, SOD activity and MDA content
As shown in table 3, the Chorispora bungeana extract has significantly inhibitory action to the reduction of Ischemia and Reperfusion in vivo in Rats tissues following MCAO in rats SOD activity, simultaneously, can effectively reduce the active and MDA content of MPO, shows that its treating cerebral ischemia and its antiinflammatory, antioxidant activity are relevant.
Table 4 Chorispora bungeana extract is on the impact (x ± s, n=8) of the MPO of rat cerebral tissue, SOD activity and MDA content
Compare with model group,
*Expression P＜0.05
*Expression P＜0.01
The anti-cerebral anoxia research of embodiment 7 Chorispora bungeana extracts
1. materials and methods
1.1 laboratory animal: the healthy adult male ICR mouse, the SPF/VAF level, body weight 18～22g is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering: SCXK (capital) 2007-0001.Using the unity and coherence in writing function of health food SPF of inspection center level experimental animal room in the Beijing Union University before the experiment conforms a week.
1.2 reagent: Chorispora bungeana: in above-mentioned Preparation Example, prepare; NAOXINTONG JIAONANG: Xianyang Buchang Pharmaceutical Co., Ltd; Sodium nitrite, the Xi'an chemical reagent factory.
1.3 instrument: AR-2140 type ten thousand/electronic balance: prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit Instr Ltd..
1.4 acute cerebral ischemia anoxia experiment
Get fasting 12h, 40 of tested ICR mices are divided into model group at random, Chorispora bungeana (being equivalent to crude drug amount 5,2.5,1.25g/kg) group, NAOXINTONG JIAONANG (0.324g/kg) group, 8 every group.Behind the mouse peritoneal drug administration by injection 2h, each treated animal pursues only broken end from cervical region, immediately by manual time-keeping, notes down rear time and the mouth breathing number of times to respiratory arrest of each treated animal broken end.
The survival experiment 1.5 sodium nitrite poisons
Get fasting 12h, 40 of tested ICR mices are divided into model group at random, Chorispora bungeana (being equivalent to crude drug amount 5,2.5,1.25g/kg) group, NAOXINTONG JIAONANG (0.324g/kg) group, 8 every group.Behind the mouse peritoneal drug administration by injection 2h, each organizes mice by 240mg/kg dosage lumbar injection sodium nitrite (concentration is 24mg/ml), take respiratory arrest as index, records respectively the mouse survival time.
1.6 statistical procedures
Experimental result all represents with x ± s, adopts one factor analysis of variance to organize a significance relatively, relatively adopts the t check between sample average.
*Expression P＜0.05 shows that administration group and model group relatively have significant difference;
*Expression P＜0.01 shows that administration group and model group relatively have utmost point significant difference.
2 results
2.1 the Chorispora bungeana extract is on the impact of chmice acute cerebral hypoxia ischemia time
Can significant prolongation break end mouth breathing time and the sodium nitrite of caused global brain ischemia mice of Chorispora bungeana extract causes death the mouse survival time, increase the frequency of respiration after mice breaks end, show that the Chorispora bungeana extract can reduce the brain oxygen consumption, improve cerebral tissue to the utilization rate of oxygen.
Table 5 Chorispora bungeana extract is on the impact (x ± s, n=8) of chmice acute cerebral hypoxia ischemia time
Compare with negative control group,
*Expression P＜0.05
*Expression P＜0.01
2.2 the Chorispora bungeana extract is on the impact of poisoning time-to-live of mice sodium nitrite
Table 6 Chorispora bungeana extract is on the impact (x ± s, n=8) of poisoning time-to-live of mice sodium nitrite
Compare with negative control group,
*Expression P＜0.05
*Expression P＜0.01
The anti-angiogenic dementia research of embodiment 8 Chorispora bungeana extracts
1. materials and methods
1.1 laboratory animal: healthy adult male ICR mouse, the cleaning level, body weight 18～20g, provided by Beijing Vital River Experimental Animals Technology Co., Ltd., use the unity and coherence in writing function of health food SPF of inspection center level experimental animal room in the Beijing Union University, Beijing Union University before the experiment and conform a week.
1.2 reagent: Chorispora bungeana: in above-mentioned Preparation Example, prepare; NAOXINTONG JIAONANG: Xianyang Buchang Pharmaceutical Co., Ltd
1.3 instrument: water maze: Anhui Province Huaibei Zhenghua Biological Instrument Co., Ltd.; Mice is kept away dark instrument: institute of Materia Medica,Chinese Academy of Medical Sciences.
1.4 set up vascular dementia model
24h fasting before the ICR mice art is freely drunk water.Anaesthetize with 4% chloral hydrate (400mg/kg, ip).Postanesthetic mice is lain on the back fixing, the cervical region preserved skin, sterilization skin cuts skin along cervical midline, separates the left and right side common carotid artery, closes blood vessel with the bulldog clamp folder, blocking-up bilateral common carotid arteries blood flow 30min.Remove bulldog clamp and pour into again, skin suture.Sham operated rats will not be pressed from both sides and be closed blood vessel, and all the other steps are the same.After pouring into 2h again, gastric infusion under the mice waking state, dosage is the same, continuously gavage 25d.
1.5 Mice water maze experiment
Before the experiment, give water filling in the water maze, the depth of water there was not 23～25 ℃ of platform 2cm water temperatures.The training the 1d mice be placed in 10s on the platform, make it be familiar with safety island, then with mice in order the head put into water from 4 quadrants successively towards tank, timing 2min, mice find platform and stop 10s thereon after, timing stops automatically.5d removes platform, and the swimming starting point of mice is 2 quadrantal points away from platform, and the platform number of times is worn in the incubation period of mice platform and record in the record 2min.
1.6 mice is kept away dark experiment
Mice is put into dorsad darkroom, bright chamber, can be shocked by electricity when mice enters into darkroom four-footed contact copper grid, its normal reaction is for withdrawing from the darkroom at once.During the 1st day adaptive training, the record mice enters the number of times in darkroom and the time that enters camera bellows the 1st time in 3min; Behind the adaptive training, open supply unit, mice is put into bright chamber and darkroom dorsad, mice enters darkroom contact copper grid and is shocked by electricity, and mice is taken out immediately.Again experiment behind the 24h, the time that the interior mice of observation 3min enters camera bellows first is incubation period, the number of times that mice enters camera bellows is errors number.
1.7 statistical procedures
Experimental result all represents with x ± s, adopts one factor analysis of variance to organize a significance relatively, relatively adopts the t check between sample average.
*Expression P＜0.05 shows that administration group and model group relatively have significant difference;
*Expression P＜0.01 shows that administration group and model group relatively have utmost point significant difference.
2. result
2.1 the Chorispora bungeana extract is on Mice water maze experiment escape latency and the impact of wearing the platform number of times
The display model group Mice water maze escape latency time increases as a result, wears the platform number of times and reduces, and learning and memory function is badly damaged.The Chorispora bungeana extract significantly reduces the water maze escape latency time, increases to wear the platform number of times, relatively has significant difference with model group.
Table 7 Chorispora bungeana extract is on Mice water maze experiment escape latency and the impact (x ± s, n=8) of wearing the platform number of times
Compare with model group,
*Expression P＜0.05
*Expression P＜0.01
2.2 the Chorispora bungeana extract is kept away the impact that dark experiment keeps away dark incubation period and wears the case number of times to mice
Compare with sham operated rats, passive the keeping away of model group mice significantly shortened dark incubation period, keeps away secretly to wear the case number of times and obviously increase.Chorispora bungeana extract doses dependency ground increases that mice is passive keeps away dark incubation period, reduces to keep away and secretly wears the case number of times.
Table 8 Chorispora bungeana extract is kept away the impact (x ± s, n=8) that dark experiment keeps away dark incubation period and wears the case number of times to mice
Compare with model group,
*Expression P＜0.05
*Expression P＜0.01
The safety evaluatio of embodiment 9 Chorispora bungeana extracts
1. materials and methods
1.1 laboratory animal: healthy adult ICR mice, cleaning level, body weight 18～22g, male and female half and half; Healthy adult W istar rat, the cleaning level, body weight 250～300g, male and female half and half, provided by Beijing Vital River Experimental Animals Technology Co., Ltd., use the unity and coherence in writing function of health food SPF of inspection center level experimental animal room in the Beijing Union University before the experiment and conform a week.
1.2 reagent: Chorispora bungeana: in above-mentioned Preparation Example, prepare;
1.3 method: 30 of mices, get at random 10 as normal control, every day the gavage distilled water; Yu 20 every day gavage give Chorispora bungeana extract (being equivalent to crude drug amount 20g/kg), continuously 2 weeks of gavage, observe the mice general state every day, food-intake is weighed.Took off cervical vertebra execution mice in 24 hours after the last administration, its internal organs outward appearance of perusal changes situation after dissecting.
Took off cervical vertebra execution animal in 24 hours after the administration, its internal organs outward appearance of perusal changes situation after dissecting.
2. result
The result shows, gives Chorispora bungeana extract 20g/kg (being equivalent to 16 times of minimum effective doses) continuous two weeks of mice, the mice general state, and food ration, body weight and internal organs show no obvious abnormalities.
Claims (7)
1. Chorispora bungeana or its extract application in preparation prevention or treatment cardiovascular and cerebrovascular diseases medicament.
2. purposes according to claim 1 is characterized in that the application in preparation prevention or treatment cerebrovascular disease medicament of Chorispora bungeana or its extract.
3. purposes according to claim 2 is characterized in that described cerebrovascular disease is cerebral ischemia, cerebral anoxia, cerebral thrombosis or vascular dementia.
4. purposes according to claim 1 is characterized in that described Chorispora bungeana extract is the Chorispora bungeana water extract.
5. purposes according to claim 1 is characterized in that described Chorispora bungeana extract is the Chorispora bungeana ethanol extract.
6. purposes according to claim 4, it is characterized in that described Chorispora bungeana water extract prepares in the following manner: a part of getting Chorispora bungeana Herb or Herb, the use pulverizer is pulverized, and soaks, and heating decocts, extract 3 times, filter, merging filtrate, centrifugal, get supernatant concentration, lyophilization becomes dry extract namely to get the Chorispora bungeana water extract.
7. purposes according to claim 5, it is characterized in that described Chorispora bungeana ethanol extract prepares in the following manner: get the Chorispora bungeana Herb, the use pulverizer is pulverized, add soak with ethanol, reflux, extract, 3 times is filtered, merging filtrate, centrifugal, get supernatant concentration, lyophilization becomes dry extract namely to get the Chorispora bungeana ethanol extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010117378 CN102138953B (en) | 2010-02-01 | 2010-02-01 | Application of chorispora bungeana or extract thereof in preparation of medicaments for preventing and treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010117378 CN102138953B (en) | 2010-02-01 | 2010-02-01 | Application of chorispora bungeana or extract thereof in preparation of medicaments for preventing and treating cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102138953A CN102138953A (en) | 2011-08-03 |
| CN102138953B true CN102138953B (en) | 2013-04-17 |
Family
ID=44406896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010117378 Expired - Fee Related CN102138953B (en) | 2010-02-01 | 2010-02-01 | Application of chorispora bungeana or extract thereof in preparation of medicaments for preventing and treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102138953B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232986A (en) * | 2010-04-21 | 2011-11-09 | 中国科学院寒区旱区环境与工程研究所 | Use of Chorispora bungeana or extract thereof in preparation of medicines for preventing and treating liver diseases |
-
2010
- 2010-02-01 CN CN 201010117378 patent/CN102138953B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 李争艳等.低温条件下高山离子芥SA的产生及NO对SA质量分数的影响.《兰州大学学报（自然科学版）》.2008,第44卷(第6期),29-33. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102138953A (en) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893549B (en) | A kind of Chinese medicine composition of fatigue alleviating and its production and use | |
| CN103417837B (en) | Medlar health preserving cream of a kind of medicine-food two-purpose and preparation method thereof | |
| US10485832B2 (en) | Chinese herbal oral paste for conditioning qi depression constitution and processing method therefor | |
| CN102771791A (en) | Healthcare food and preparation method and application thereof | |
| CN107397208B (en) | Functional food containing fish glue as main component and its use | |
| CN104366510A (en) | Tea leaf theanine health-care food composition and preparation method thereof | |
| CN101708048B (en) | Health-care food and preparation method thereof | |
| CN101862374A (en) | Lotus plumule and new application of extractive thereof | |
| KR20110128384A (en) | The composition material and the manufacturing process for skin-wrinkle, moisture and skin-lightening uses by midam-kyungokko | |
| CN102138953B (en) | Application of chorispora bungeana or extract thereof in preparation of medicaments for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN102138967A (en) | Application of dracocephalum moldavica L. general flavone in preparing medicament for preventing and treating cerebrovascular disease | |
| CN102125576A (en) | Application of liquiritin in preparing medicine for treating cardiovascular and cerebrovascular diseases | |
| CN101143203A (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN101884758B (en) | Food therapy preparation for preventing and treating cerebrovascular diseases based on theories of preventive treatment of disease and medicine food homology | |
| CN106138795B (en) | Traditional Chinese medicine composition for treating premature beat and preparation method thereof | |
| CN101124990A (en) | New use of humulus scandens in preparing medicine for resisting fatigue and resisting oxygen deficit or health-care food | |
| CN108685961A (en) | A kind of improvement learning and memory composition and preparation, preparation method and application | |
| CN112843155B (en) | Composition suitable for puerpera and used for removing freckles and relieving lumbago | |
| CN103845581A (en) | Natural green composition and application thereof to preventing and treating diabetes | |
| CN106975068A (en) | A kind of pigskin collagen small peptide active component composition | |
| CN106540011A (en) | The pharmaceutical composition of preventing and treating senile osteoporosis | |
| KR20180133271A (en) | Preparations using herbal medicine extracts and powders and their manufacturing methods | |
| CN106822206A (en) | It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof | |
| CN106727495B (en) | A kind of flavanone compound is preparing the application in myocardial preservation drug | |
| CN100384437C (en) | Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130417 Termination date: 20160201 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |